Concizumab

Last Updated: 06/30/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 81 publications

Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B.

Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B.

Journal: The Cochrane database of systematic reviews
Published: March 24, 2026

Comparative Efficacy and Safety of Non-Clotting Factor Prophylaxis Versus. on-Demand Therapy in Hemophilia: A Meta-Analysis of Randomized Controlled Trials.

Comparative Efficacy and Safety of Non-Clotting Factor Prophylaxis Versus. on-Demand Therapy in Hemophilia: A Meta-Analysis of Randomized Controlled Trials.

Journal: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Published: March 03, 2026

Real-World Effectiveness and Safety of Concizumab Prophylaxis in Hemophilia: Results From a National French Cohort.

Real-World Effectiveness and Safety of Concizumab Prophylaxis in Hemophilia: Results From a National French Cohort.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: February 25, 2026

Challenges in Balancing Hemostasis and Thrombosis in Therapy Tailoring for Hemophilia: A Narrative Review.

Challenges in Balancing Hemostasis and Thrombosis in Therapy Tailoring for Hemophilia: A Narrative Review.

Journal: International journal of molecular sciences
Published: November 26, 2025

Concizumab in hemophilia with inhibitors: longer-term efficacy and safety results from the phase 3 explorer7 study.

Concizumab in hemophilia with inhibitors: longer-term efficacy and safety results from the phase 3 explorer7 study.

Journal: Blood advances
Published: September 03, 2025

Concizumab in hemophilia with inhibitors: Longer-term efficacy and safety results from the phase 3 explorer7 study.

Concizumab in hemophilia with inhibitors: Longer-term efficacy and safety results from the phase 3 explorer7 study.

Journal: Blood advances
Published: September 03, 2025

Concizumab use in toddlers with hemophilia B and inhibitors real-world data from an international collaboration.

Concizumab use in toddlers with hemophilia B and inhibitors real-world data from an international collaboration.

Journal: Journal of thrombosis and haemostasis : JTH
Published: July 15, 2025

Rebalancing therapy for congenital hemophilia

Rebalancing therapy for congenital hemophilia

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: July 06, 2025

Curative Therapies for Hemophilias and Hemoglobinopathies in Adults: Immune, Gene, and Stem Cell Approaches in a Global Context.

Curative Therapies for Hemophilias and Hemoglobinopathies in Adults: Immune, Gene, and Stem Cell Approaches in a Global Context.

Journal: Biomedicines
Published: July 06, 2025

Fitusiran (Qfitlia) for hemophilia A and B.

Fitusiran (Qfitlia) for hemophilia A and B.

Journal: The Medical letter on drugs and therapeutics
Published: July 02, 2025

Pharmacokinetic evaluation of concizumab for the treatment of hemophilia.

Pharmacokinetic evaluation of concizumab for the treatment of hemophilia.

Journal: Expert opinion on drug metabolism & toxicology
Published: June 23, 2025

Investigation of the Suitability of the ROTEM Assay to Measure Coagulation Potential in Blood From Patients on Concizumab Prophylaxis.

Investigation of the Suitability of the ROTEM Assay to Measure Coagulation Potential in Blood From Patients on Concizumab Prophylaxis.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: June 20, 2025
Showing 1-12 of 81

Last Updated: 06/30/2026